By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Afferent Pharmaceuticals 

29 Newbury Street
Suite 301
Boston  Massachusetts  02116  U.S.A.
Phone: 617-859-3099 Fax: 617-859-2891




Company News
Afferent Pharmaceuticals Announces Positive Results In Phase 2b Chronic Cough Trial 9/28/2015 1:30:17 PM
Afferent Pharmaceuticals Raises $55 Million In Oversubscribed Crossover Financing 7/8/2015 8:22:45 AM
Afferent Pharmaceuticals Announces The Election Of Dr. Peter Hirth To The Company’s Board Of Directors 12/3/2014 8:45:11 AM
Afferent Pharmaceuticals Clinical Data Demonstrating AF-219 Treatment Reduces Cough Frequency By 75% in Chronic Cough Is Published In The Lancet 11/25/2014 6:37:44 AM
Afferent Pharmaceuticals Names Kathleen Sereda Glaub As Chief Executive Officer 9/10/2014 6:27:42 AM
Afferent Pharmaceuticals Names Michael M. Kitt, M.D., as Chief Medical Officer 11/6/2013 9:15:37 AM
Afferent Pharmaceuticals Reports Positive Phase 2 Clinical Data for the Company’s Lead P2X3 Antagonist, AF-219 9/9/2013 9:44:08 AM
Afferent Pharmaceuticals Presents Data Supporting Use of P2X3 Antagonists in Reducing Bone Cancer Pain 9/1/2010 8:42:05 AM
Afferent Pharmaceuticals Announces Data Supporting Potential Utility of Proprietary P2X3 Antagonists in Regulating Bladder Reflexes 8/25/2010 10:12:23 AM
Roche (RHHBY) (JOBS) Licenses First-in-Class Treatments for Chronic Pain to Afferent Pharmaceuticals; Afferent Secures $23 Million in Series A Financing 12/16/2009 6:31:41 AM